Belite Bio Announces FDA Acceptance And Priority Review Of Tinlarebant NDA For Stargardt Disease Type 1, With PDUFA Date Of February 12, 202
Belite Bio Announces FDA Acceptance And Priority Review Of Tinlarebant NDA For Stargardt Disease Type 1, With PDUFA Date Of February 12, 2027
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.